Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Price to FCFE (P/FCFE)

Microsoft Excel

Free Cash Flow to Equity (FCFE)

Regeneron Pharmaceuticals Inc., FCFE calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income 4,412,600 3,953,600 4,338,400 8,075,300 3,513,200
Net noncash charges 626,200 734,500 919,800 922,500 608,500
Changes in assets and liabilities (618,300) (94,100) (243,300) (1,916,500) (1,503,600)
Net cash provided by operating activities 4,420,500 4,594,000 5,014,900 7,081,300 2,618,100
Capital expenditures (755,900) (718,600) (590,100) (551,900) (614,600)
Proceeds from sale of property, plant, and equipment 20,100 — — — —
Proceeds from issuance of long-term debt — — — — 1,981,900
Proceeds from bridge loan facility — — — — 1,500,000
Repayment of bridge loan facility — — — — (1,500,000)
Free cash flow to equity (FCFE) 3,684,700 3,875,400 4,424,800 6,529,400 3,985,400

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Item Description The company
FCFE Free cash flow to equity is the cash flow available to Regeneron Pharmaceuticals Inc. equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. Regeneron Pharmaceuticals Inc. FCFE decreased from 2022 to 2023 and from 2023 to 2024.

Price to FCFE Ratio, Current

Regeneron Pharmaceuticals Inc., current P/FCFE calculation, comparison to benchmarks

Microsoft Excel
No. shares of common stock outstanding 109,324,682
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in thousands) 3,684,700
FCFE per share 33.70
Current share price (P) 637.36
Valuation Ratio
P/FCFE 18.91
Benchmarks
P/FCFE, Competitors1
AbbVie Inc. 14.45
Amgen Inc. 26.88
Bristol-Myers Squibb Co. 5.07
Danaher Corp. 40.42
Eli Lilly & Co. 61.60
Gilead Sciences Inc. 11.80
Johnson & Johnson 13.19
Merck & Co. Inc. 11.05
Pfizer Inc. 53.39
Thermo Fisher Scientific Inc. 38.34
Vertex Pharmaceuticals Inc. —
P/FCFE, Sector
Pharmaceuticals, Biotechnology & Life Sciences 19.86
P/FCFE, Industry
Health Care 18.31

Based on: 10-K (reporting date: 2024-12-31).

1 Click competitor name to see calculations.

If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.

Price to FCFE Ratio, Historical

Regeneron Pharmaceuticals Inc., historical P/FCFE calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
No. shares of common stock outstanding1 109,324,682 109,761,896 109,325,532 108,539,282 107,131,899
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in thousands)2 3,684,700 3,875,400 4,424,800 6,529,400 3,985,400
FCFE per share3 33.70 35.31 40.47 60.16 37.20
Share price1, 4 716.72 936.33 780.86 622.36 494.90
Valuation Ratio
P/FCFE5 21.27 26.52 19.29 10.35 13.30
Benchmarks
P/FCFE, Competitors6
AbbVie Inc. 13.57 17.37 22.66 18.76 13.16
Amgen Inc. 25.50 4.71 8.32 13.52 11.06
Bristol-Myers Squibb Co. 4.74 7.52 22.85 16.17 7.80
Danaher Corp. 40.83 53.08 32.04 20.75 44.62
Eli Lilly & Co. 64.93 75.06 60.51 35.17 36.62
Gilead Sciences Inc. 12.07 12.81 15.22 12.70 5.98
Johnson & Johnson 12.67 24.31 16.73 23.28 15.60
Merck & Co. Inc. 11.32 24.48 22.40 18.72 17.85
Pfizer Inc. 55.28 3.82 10.56 8.88 —
Thermo Fisher Scientific Inc. 41.23 31.16 27.98 13.44 18.58
Vertex Pharmaceuticals Inc. — 33.45 19.91 26.08 18.46
P/FCFE, Sector
Pharmaceuticals, Biotechnology & Life Sciences 19.99 16.91 19.28 16.49 17.09
P/FCFE, Industry
Health Care 18.23 16.85 18.12 17.81 17.23

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Data adjusted for splits and stock dividends.

2 See details »

3 2024 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= 3,684,700,000 ÷ 109,324,682 = 33.70

4 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.

5 2024 Calculation
P/FCFE = Share price ÷ FCFE per share
= 716.72 ÷ 33.70 = 21.27

6 Click competitor name to see calculations.

Valuation ratio Description The company
P/FCFE Price to free cash flow to equity is cash valuation indicator of stockholders’ equity. Regeneron Pharmaceuticals Inc. P/FCFE ratio increased from 2022 to 2023 but then slightly decreased from 2023 to 2024 not reaching 2022 level.